Eddid Financial and Asseto Forge Strategic Partnership to Pioneer Global Asset Tokenisation and Financial Ecosystem Innovationby krapalmJune 1, 2026PR Newswire
ASCO 2026 | Oricell’s GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potentialby krapalmJune 1, 2026PR Newswire
Calibrite Display Plus HL Receives Apple Approval for Hardware-Level Display Calibrationby krapalmJune 1, 2026PR Newswire
Traveloka 6.6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelersby krapalmJune 1, 2026PR Newswire
Deloitte appoints Robert Hillard as Asia Pacific Chief Executive Officerby krapalmJune 1, 2026PR Newswire
BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocationsby krapalmJune 1, 2026PR Newswire
UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunitiesby krapalmJune 1, 2026PR Newswire
Hankook’s Ventus Delivers Unwavering Performance Throughout WRC FORUM8 Rally Japan’s Ever-Changing Conditionsby krapalmJune 1, 2026PR Newswire
Investor repositioning drives shift in Asia quant markets, BofA Securities conference showsby krapalmJune 1, 2026PR Newswire
Mahindra and Manulife Insurance JV Moves Ahead; Gets Approval from Ministry of Corporate Affairsby krapalmJune 1, 2026PR Newswire
Xinhua Silk Road: 2026 RCEP Local Governments and Friendship Cities Cooperation (Huangshan) Forum opens in E China’s Anhuiby krapalmJune 1, 2026PR Newswire
MICROIP to Debut “AI Vehicle System Business Group” and Edge AI Innovations at COMPUTEX 2026by krapalmJune 1, 2026PR Newswire
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLCby krapalmJune 1, 2026PR Newswire
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interviewby krapalmJune 1, 2026PR Newswire
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCOby krapalmJune 1, 2026PR Newswire
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLCby krapalmJune 1, 2026PR Newswire
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancerby krapalmJune 1, 2026PR Newswire
New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026by krapalmJune 1, 2026PR Newswire
